- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Regeneron Pharmaceuticals Inc (REGN)
Track today's live Regeneron Pharmaceuticals (REGN) share price, performance and key data on this page with our current NASDAQ:REGN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Regeneron Pharmaceuticals share price on the NASDAQ exchange. Use the dropdown to switch exchange for the REGN share price, head to our technical summary section, which provides analysis on Regeneron Pharmaceuticals share price buy/sell indicators using real-time data (or discuss the Regeneron Pharmaceuticals (REGN) stock price today with other investors in the Regeneron Pharmaceuticals NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:REGN share price (ISIN: US75886F1075) to enhance your trading decisions with our free investment tools and resources.
What Is the Regeneron Pharmaceuticals Inc Share Price Today?
The Regeneron Pharmaceuticals share price today is 731.47.
What Is the Stock Symbol for Regeneron Pharmaceuticals Inc
The stock symbol (or 'ticker') for Regeneron Pharmaceuticals Inc is "REGN."
What Stock Exchange Does Regeneron Pharmaceuticals Inc Trade On?
Regeneron Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Regeneron Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Regeneron Pharmaceuticals (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:REGN share price (ISIN: US75886F1075) to enhance your trading decisions with our free investment tools and resources.
What Is the Regeneron Pharmaceuticals Inc Share Price Today?
The Regeneron Pharmaceuticals share price today is 731.47.
What Is the Stock Symbol for Regeneron Pharmaceuticals Inc
The stock symbol (or 'ticker') for Regeneron Pharmaceuticals Inc is "REGN."
What Stock Exchange Does Regeneron Pharmaceuticals Inc Trade On?
Regeneron Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Regeneron Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Regeneron Pharmaceuticals (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
731.47
-3.74(-0.51%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
722.02
736.42
52 wk Range
541.00
859.34
REGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
722.02736.42
52 wk Range
541.00859.34
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.51%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.51%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
REGN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
853.19
Upside
+16.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
18 Buy
8 Hold
1 Sell
Ratings:
27 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 853.19
(+16.64% Upside)
Regeneron Pharmaceuticals Inc SWOT Analysis
Eylea's Challenges | Explore Regeneron's strategy to maintain Eylea's market position amid biosimilar competition and regulatory hurdles, impacting its $4 billion franchise |
Dupixent's Ascent | Discover how Dupixent's expansion into new indications could drive Regeneron's growth, with analysts projecting an 8% CAGR from 2025 to 2030 |
Pipeline Potential | Delve into Regeneron's promising oncology and immunology pipeline, including fianlimab for melanoma and itepekimab for COPD |
Financial Outlook | Analysts maintain a positive outlook with EPS estimates around $34.50 for 2025. Price targets range from $695 to $1,215, averaging around $990 |
Regeneron Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- Regeneron posted Q2 2026 revenue of $4.29B, up 17% YoY, and non-GAAP EPS of $14.29, beating estimates by 35.1% and 12.9% respectively.
- Dupixent drove growth with $6.0B in global sales, up 38% constant-currency; Eylea HD U.S. sales surpassed legacy Eylea for the first time.
- Sanofi collaboration revenue hit record $2.2B; development balance fully repaid, enabling higher profit share starting Q3 2026.
- Company expects Dupixent growth to moderate in H2 2026 on tougher comps; Eylea HD to grow low-to-mid teens sequentially while legacy Eylea declines.
- FDA decisions expected for garetosmab in August and cemdisiran in November; company maintains $15.1B cash position and repurchased $1.2B shares in Q2.
Last Updated: 30/07/2026, 15:04
Read Full TranscriptEarnings
Latest Release
30/07/2026
EPS / Forecast
14.29 / 10.58
Revenue / Forecast
4.29B / 3.8B
Compare REGN to Peers and Sector
Metrics to compare | REGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 16.7x | 21.1x | −0.3x | |
PEG Ratio | 8.86 | −0.39 | 0.00 | |
Price/Book | 2.3x | 3.3x | 2.6x | |
Price / LTM Sales | 4.7x | 2.8x | 3.0x | |
Upside (Analyst Target) | 16.0% | 32.0% | 58.6% | |
Fair Value Upside | Unlock | 13.2% | 7.4% | Unlock |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Regeneron Pharmaceuticals (NASDAQ: REGN) Share Price Today?
The Regeneron Pharmaceuticals stock price today is 731.47 USD.
What Stock Exchange Does Regeneron Pharmaceuticals (REGN) Trade On?
Regeneron Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Regeneron Pharmaceuticals?
The stock symbol (also called a 'ticker') for Regeneron Pharmaceuticals is "REGN."
Does Regeneron Pharmaceuticals Pay Dividends? What’s The Current REGN Dividend Yield?
Yes, REGN Pays Dividends to its Shareholders. The current Regeneron Pharmaceuticals dividend yield is 0.51%.
What Is the Current Regeneron Pharmaceuticals Market Capitalisation?
As of today, Regeneron Pharmaceuticals (NASDAQ: REGN) market cap is 72.30B USD.
What Is Regeneron Pharmaceuticals's (REGN) Earnings Per Share (TTM)?
The Regeneron Pharmaceuticals EPS is currently 40.43 (Trailing Twelve Months).
When Is the Next Regeneron Pharmaceuticals Earnings Date?
Regeneron Pharmaceuticals's next earnings report will be released on 30/10/2026.
Is REGN a Buy or Sell From a Technical Analyst Perspective?
Based on today's Regeneron Pharmaceuticals moving averages and other technical indicators, the daily buy/sell signal for REGN stock is Strong Sell.
How Many Times Has Regeneron Pharmaceuticals Stock Split?
Regeneron Pharmaceuticals has split 0 times. (See the REGN stock split history page for full effective split date and price information.)
How Many Employees Does Regeneron Pharmaceuticals Have?
Regeneron Pharmaceuticals has 15410 employees, based on their latest Companies House report.
What is the current trading status of Regeneron Pharmaceuticals (NASDAQ: REGN)?
As of 05/10/2026, Regeneron Pharmaceuticals (REGN) is trading at a share price of 731.47 USD, with a previous close of 735.20 USD. The stock has fluctuated within a day range of 722.02 USD to 736.42 USD, while its 52-week range spans from 541.00 USD to 859.34 USD.
What Is Regeneron Pharmaceuticals (REGN) Price Target According to Analysts?
The average 12-month price target for Regeneron Pharmaceuticals is 853.19 USD, with a high estimate of 1030 USD and a low estimate of 730 USD. 18 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +16.64% Upside potential.
What Is the REGN Premarket Price?
REGN's last pre-market stock price is 734.86 USD. The pre-market share volume is 330.00, and the stock has decreased by -0.34, or -0.05%.
What Is the REGN After Hours Price?
REGN's last after hours stock price is 735.00 USD, the stock has decreased by -0.20, or -0.03%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.